Results 21 to 30 of about 10,726 (197)

Genetic variance in CYP2C8 and increased risk of myocardial infarction

Pharmacogenetics and Genomics, 2010
Background Epoxyeicosatrienoic acids (EETs) are important mediators in vasodilatation, acting as endothelium-derived hyperpolarizing factors. CYP2C enzymes catalyze the metabolism of arachidonic acid to EETs.
Witteman, JCM, Uitterlinden, André, Stricker, Bruno, Visser, Loes, Uitterlinden, André; id_orcid, Hofman, Bert, Rodenburg, Eline, Danser, Jan, Noord, Charlotte   +8 more
core   +4 more sources

Amiodarone N‐Deethylation by CYP2C8 and its Variants, CYP2C8*3 and CYP2C8 P404A [PDF]

Pharmacology & Toxicology, 2002
Abstract: Amiodarone is a potent Class III antiarrhythmic drug. The N‐deethylation of amiodarone to desethylamiodarone is known to be catalyzed by cytochrome P450 (CYP) 2C8. In the present study, amiodarone N‐deethylation by the CYP2C8s, CYP2C8*1 (wild‐type), CYP2C8*3, and CYP2C8 P404A (Pro404Ala substitution in exon 8), was investigated by their ...
Akiko, Soyama, Nobumitsu, Hanioka, Yoshiro, Saito, Norie, Murayama, Masanori, Ando, Shogo, Ozawa, Jun-ichi, Sawada   +6 more
openaire   +2 more sources

CYP2C8 and Antimalaria Drug Efficacy [PDF]

Pharmacogenomics, 2007
Malaria is a major infectious disease. In the last 10 years it has killed more than 20 million people, mainly small children in Africa. The highly efficacious artemisinine combination therapy is being launched globally, constituting the main hope for fighting the disease. Amodiaquine is a main partner in these combinations.
Gil, JP, Gil Berglund, E
openaire   +2 more sources

Pioglitazone is Metabolised by CYP2C8 and CYP3A4 in vitro: Potential for Interactions with CYP2C8 Inhibitors [PDF]

Basic & Clinical Pharmacology & Toxicology, 2006
Abstract: Our objective was to identify the cytochrome P450 (CYP) enzymes that metabolise pioglitazone and to examine the effects of the CYP2C8 inhibitors montelukast, zafirlukast, trimethoprim and gemfibrozil on pioglitazone metabolism in vitro. The effect of different CYP isoform inhibitors on the elimination of a clinically relevant concentration of
Tiina, Jaakkola, Jouko, Laitila, Pertti J, Neuvonen, Janne T, Backman   +3 more
openaire   +2 more sources

Effect of quercetin on the pharmacokinetics of selexipag and its active metabolite in beagles

Pharmaceutical Biology, 2022
Context As an inhibitor cytochrome P450 family 2 subfamily C polypeptide 8 (CYP2C8), quercetin is a naturally occurring flavonoid with its glycosides consumed at least 100 mg per day in food.
Shun-bin Luo, Er-min Gu, Yu-ao Chen, Shi-chen Zhou, Chen Fan, Ren-ai Xu   +5 more
doaj   +1 more source

Structure of the distribution of genetic determinants of the efficacy and safety of non-steroidal anti-inflammatory drugs in the Russian population: focus on CYP2C8, PTGS1 and PTGS2

Современная ревматология, 2022
The efficacy and safety of non-steroidal anti-inflammatory drugs (NSAIDs) may be determined by the polymorphic nature of the CYP2C8, PTGS1 and PTGS2 genes.Objective: to analyze the nature of the distribution of CYP2C8*3 (rs10509681), CYP2C8*3 (rs11572080)
N. P. Denisenko, Sh. P. Abdullaev, K. A. Akmalova, Zh. A. Sozaeva, A. A. Kachanova, M. S-Kh. Sozaeva, L. Z. Bolieva, E. A. Grishina, D. A. Sychev   +8 more
doaj   +1 more source

CYP2C8 but not CYP3A4 is important in the pharmacokinetics of montelukast [PDF]

British Journal of Clinical Pharmacology, 2012
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT• The elimination of montelukast occurs mainly via metabolism and, according to its product information, CYP3A4 and 2C9 are the main metabolizing enzymes in vitro.• Recent studies, however, suggest that CYP2C8 may have a role in the metabolism of montelukast.WHAT THIS STUDY ADDS• The CYP3A4 inhibitor itraconazole
Tiina, Karonen, Pertti J, Neuvonen, Janne T, Backman   +2 more
openaire   +2 more sources

Distribution of the cytochrome P450 CYP2C8*2 allele in Brazzaville, Republic of Congo

International Journal of Infectious Diseases, 2019
Background: Cytochrome P450 (CYP) enzymes are essential in the metabolism of most drugs used today. Single nucleotide polymorphism(s) occurring in CYP genes can adversely affect drug pharmacokinetics, efficacy, and safety. Individuals carrying the CYP2C8*
Simon Marie Peko, Francine Ntoumi, Christevy Vouvoungui, David Nderu, Simon Charles Kobawila, Thirumalaisamy P. Velavan, Félix Koukouikila-Koussounda   +6 more
doaj   +1 more source

Analysis of the functional polymorphism in the cytochrome P450 CYP2C8 gene rs11572080 with regard to colorectal cancer risk

Frontiers in Genetics, 2012
In addition to the known effects on drug metabolism and response, functional polymorphisms of genes coding for xenobiotic-metabolizing enzymes (XME) play a role in cancer.
José M Ladero, José A G Agúndez, Carmen eMartínez, Gemma eAmo, Pedro eAyuso, Elena eGarcía-Martín   +5 more
doaj   +1 more source

Pharmacogenetic Aspects of Type 2 Diabetes Treatment

Acta Biomedica Scientifica, 2020
In this article, we analyze the role of different variants of the KCNJ11, TCF7L2, SLC22A1, SLC22A3, CYP2C9, CYP2C8, PPARγ genes polymorphisms in efficacy of diabetes mellitus pharmacotherapy.
N. O. Pozdnyakov, I. N. Kagarmanyan, A. E. Miroshnikov, E. S. Emelyanov, A. A. Gruzdeva, A. M. Sirotkina, I. A. Dukhanina, A. A. Milkina, A. A. Khokhlov, S. O. Pozdnyakov   +9 more
doaj   +1 more source